Target Name: OR2AK2
NCBI ID: G391191
Review Report on OR2AK2 Target / Biomarker Content of Review Report on OR2AK2 Target / Biomarker
OR2AK2
Other Name(s): Olfactory receptor OR1-47 | OR1-47 | olfactory receptor OR1-47 | O2AK2_HUMAN | Olfactory receptor 2AK2 | Olfactory receptor 2AK1 | olfactory receptor family 2 subfamily AK member 2 | olfactory receptor, family 2, subfamily AK, member 1 pseudogene | Olfactory receptor, family 2, subfamily AK, member 1 pseudogene | OR2AK1P | Olfactory receptor family 2 subfamily AK member 2 | olfactory receptor 2AK1

OR1-47: A Potential Drug Target Or Biomarker for Various Diseases

Olfactory receptor OR1-47 is a protein that is expressed in the sweat glands and is responsible for sensing odor. Recent studies have suggested that OR1-47 may have potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the reasons for the potential of OR1-47 as a drug target is its unique structure. OR1-47 is a transmembrane protein that consists of an extracellular region, a transmembrane region, and an intracellular region. The transmembrane region of OR1-47 contains an extracellular portion that is involved in cell-cell signaling, while the intracellular region contains a portion that is involved in the intracellular signaling cascade.

Studies have shown that OR1-47 is involved in several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. The TGF-β pathway is a well-known signaling pathway that is involved in the development and maintenance of tissues, while the NF-kappa-B pathway is a signaling pathway that is involved in inflammation and stress responses.

In addition to its involvement in these signaling pathways, OR1-47 has also been shown to play a role in several diseases. For example, OR1-47 has been shown to be involved in the development of cancer, particularly breast cancer. Studies have shown that high levels of OR1-47 are associated with the development of breast cancer and that inhibiting OR1-47 signaling can be a potential therapeutic approach for this disease.

Another potential application of OR1-47 as a drug target is its involvement in neurodegenerative diseases. OR1-47 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that OR1-47 is involved in the production of amyloid peptides, which are a hallmark of neurodegenerative diseases, and that inhibiting OR1-47 signaling can be a potential therapeutic approach for these diseases.

In addition to its involvement in neurodegenerative diseases, OR1-47 has also been shown to be involved in psychiatric disorders. OR1-47 has been shown to be involved in the development of anxiety and depression, and studies have shown that low levels of OR1- 47 are associated with symptoms of anxiety and depression.

In conclusion, OR1-47 is a protein that is expressed in the sweat glands and is involved in the sense of smell. Recent studies have suggested that OR1-47 may have potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The unique structure of OR1-47 and its involvement in several signaling pathways make it an attractive target for further research. Further studies are needed to fully understand the role of OR1-47 in these diseases and to develop safe and effective therapies that can be used to treat them.

Protein Name: Olfactory Receptor Family 2 Subfamily AK Member 2

Functions: Odorant receptor

The "OR2AK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2AK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15